A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Clinical Cancer Research, 06/15/2012
Hong DS et al. – Bardoxolone methyl was well tolerated with an maximum tolerated dose (MTD) of 900mg/d. The increase in estimated glomerular filtration rate (eGFR) suggests that bardoxolone methyl might be beneficial in chronic kidney disease. Objective tumor responses and pharmacodynamic effects were observed, supporting continued development of other synthetic triterpenoids in cancer.